PLEKHA1

Across TCGA pan-cancer cohorts, PLEKHA1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLEKHA1 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PLEKHA1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PLEKHA1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where PLEKHA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.985	0.912	.026	5	view →
LUAD	DFS	Tertile	II,III,IV	0.361	0.684	.030	5	view →
CCRCC	DFS	Median	All	1.000	0.733	.020	3	view →
UCEC	OS	Tertile	All	1.000	0.914	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLEKHA1–HNSC (DFS)

Open the HNSC breakdown →